Abivax (ABVX) Interest & Investment Income (2024 - 2026)
Abivax (ABVX) posted quarterly Interest & Investment Income of $14.9 million for Q1 2026, up 815.0% year-over-year from $1.6 million in Q1 2025, and up 167.23% on a QoQ basis from $5.6 million in Q4 2025.
Abivax (ABVX) Interest & Investment Income (2024 - 2026) Analysis & Trends
Abivax (ABVX) has reported Interest & Investment Income for 3 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 815.0% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $48.3 million (up 262.41% YoY), while the FY2025 annual figure was $32.1 million, up 118.51% from the prior year.
- Interest & Investment Income came in at $14.9 million for Q1 2026 at Abivax, up from $5.6 million in the prior quarter.
- The five-year high for Interest & Investment Income was $23.9 million in Q3 2025, with the low at $1.6 million in Q1 2025.
- Average Interest & Investment Income over 3 years is $7.6 million, with a median of $4.0 million recorded in 2024.
- Across the five-year window, Interest & Investment Income tumbled 75.08% in 2025 and jumped 815.0% in 2026, its largest moves.
- Year by year, Interest & Investment Income stood at $4.0 million in 2024, then surged by 38.27% to $5.6 million in 2025, then soared by 167.23% to $14.9 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $14.9 million, $5.6 million, and $23.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 44.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | - |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 27.66 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 114.80 Mn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | - |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | - |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 44.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 26.60 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | 19.51 Mn |
| 10 | Abivax | - | - | - | 14.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.94 Mn |
| Dec 31, 2025 | 5.59 Mn |
| Sep 30, 2025 | 23.85 Mn |
| Jun 30, 2025 | 3.96 Mn |
| Mar 31, 2025 | 1.63 Mn |
| Dec 31, 2024 | 4.04 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Jun 30, 2024 | 3.89 Mn |
| Mar 31, 2024 | 6.55 Mn |